Trial · NCT04729972

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

NCT04729972, Phase 2, Completed, Neurotech Pharmaceuticals; results first posted 2025-03-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2. Trials, record NCT04729972. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04729972

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
NCT number: NCT04729972
Status: Completed
Phases: Phase 2
Enrollment: 33 participants, actual
Lead sponsor: Neurotech Pharmaceuticals
Conditions: Macular Telangiectasia Type 2
Interventions: NT-501 CNTF implant
First posted: 2021-01-29
Last updated: 2025-03-26
Results first posted: 2025-03-26

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	6 months	Assess the incidence and severity of adverse events (AEs) following bilateral ocular implantation of NT-501
Secondary	Serum Levels of CNTF and Immunogenicity for NT-501	6 months	Incidence of positive serum levels of CNTF and immunogenicity for NT-501 with quantification of antibodies (Ab) to CNTF, neutralizing antibodies (NAb) to CNTF, Ab to NTC-201-6A cells, and Ab to mouse dihydrofolate reductase (mDHFR) at any time.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	6 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Serum Levels of CNTF and Immunogenicity for NT-501	6 months	A neutralizing antibody test to NT-501-produced CNTF was performed to verify or refute CNTF antibody detected in one participant. The neutralizing antibody test refuted that the antibody detected was to NT-501 CNTF.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group13

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	At least 1 TEAE	26	Participants
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	At least 1 ocular TEAE in study eye	26	Participants
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	At least 1 ocular TEAE in fellow eye	6	Participants
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	At least 1 nonocular TEAE	13	Participants
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	At least 1 treatment related ocular TEAE	26	Participants
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	At least 1 treatment related nonocular TEAE	0	Participants
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	At least 1 SAE	2	Participants
Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events	NT-501 in Fellow Eye	NT-501 removal from either eye	0	Participants
Serum Levels of CNTF and Immunogenicity for NT-501	NT-501 in Fellow Eye	CNTF Positive	0	Participants
Serum Levels of CNTF and Immunogenicity for NT-501	NT-501 in Fellow Eye	Ab Positive to CNTF	1	Participants

1 to 10 of 13Source ClinicalTrials.gov

See all 13 results by group

Participant flow4

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	NT-501 in Fellow Eye	33
Overall Study	NT-501 Implanted in Study Eye	NT-501 in Fellow Eye	32
Overall Study	COMPLETED	NT-501 in Fellow Eye	32
Overall Study	NOT COMPLETED	NT-501 in Fellow Eye	1

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Eye pain	Eye disorders	NT-501 in Fellow Eye	9	32	9
other	Ocular discomfort	Eye disorders	NT-501 in Fellow Eye	9	32	9
other	Conjunctival haemorrhage	Eye disorders	NT-501 in Fellow Eye	8	32	8
other	Eye irritation	Eye disorders	NT-501 in Fellow Eye	4	32	4
other	Dry eye	Eye disorders	NT-501 in Fellow Eye	2	32	2
other	Anterior chamber cell	Eye disorders	NT-501 in Fellow Eye	1	32	1
other	Anterior chamber flare	Eye disorders	NT-501 in Fellow Eye	1	32	1
other	Cataract	Eye disorders	NT-501 in Fellow Eye	1	32	1
other	Cataract subcapsular	Eye disorders	NT-501 in Fellow Eye	1	32	1
other	Conjunctival hyperaemia	Eye disorders	NT-501 in Fellow Eye	1	32	1

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	NT-501 in Fellow Eye	0	32
Total, other adverse events	NT-501 in Fellow Eye	26	32
Total, serious adverse events	NT-501 in Fellow Eye	2	32

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30292541	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04729972

GET https://conductscience.org/api/trials/v1/NCT04729972/events?page=2

API reference For AI assistants